SeungJae Baek (Seungjae Baek)

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 7

Top Topics

Placebo Controlled

Cardiovascular Disease

Top Venues

Diabetes, obesity & metabolism

Pharmaceuticals (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Vanita R Aroda, Juan Pablo Frias, Li-Nong Ji, Elisabeth Niemoeller, My-Liên Nguyên-Pascal, Karl Denkel, Melanie Espinasse, Hailing Guo, SeungJae Baek, JaeDuk Choi, Ildiko Lingvay
Efficacy and Safety of Once-Weekly Efpeglenatide in People with Suboptimally Controlled Type 2 Diabetes: The AMPLITUDE-D, AMPLITUDE-L and AMPLITUDE-S Randomised Controlled Trials. Diabetes, obesity & metabolism (2023)
Ulagamadesan Venkatesan, Zhuoru Li, Chinthanie Ramasundarahettige, SeungJae Baek, Kelley R H Branch, Stephano Del Prato, Carolyn Su Ping Lam, Renato Deláscio Lopes, Richard E Pratley, Julio Rosenstock, Naveed Sattar
Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial. Circulation (2023)
Jihye Kim, Nakho Chang, Yunki Kim, Jaehyun Lee, Daeseok Oh, Jaeyoung Choi, Onyou Kim, Sujin Kim, Myongho Choi, Junyeob Lee, Junghwa Lee, Jungyul Kim, Minji Cho, Minsu Kim, Kwanghwan Lee, Dukhyun Hwang, Jason K Sa, Sungjin Park, SeungJae Baek, Daeseong Im
The Novel Tetra-Specific Drug C-192, Conjugated Using UniStac, Alleviates Non-Alcoholic Steatohepatitis in an MCD Diet-Induced Mouse Model. Pharmaceuticals (Basel, Switzerland) 16 (11) (2023)
Wonjung Shin, Marcus Hompesch, JinHee Byeon, Seohyun Kang, Jaehyuk Choi, SeungJae Baek
Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of the novel long-acting glucagon analogue HM15136 in overweight and obese patients with co-morbidities. Diabetes, obesity & metabolism (2023)
Juan Pablo Frias, JaeDuk Choi, Julio Rosenstock, Luiza Popescu, Elisabeth Niemoeller, Isabel Muehlen-Bartmer, SeungJae Baek
Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial. Diabetes care 45 (7) (2022)
Carolyn Su Ping Lam, Chinthanie Ramasundarahettige, Kelley R H Branch, Naveed Sattar, Julio Rosenstock, Richard E Pratley, Stephano Del Prato, Renato Deláscio Lopes, Elisabeth Niemoeller, Nardev S Khurmi, SeungJae Baek, Hertzel C Gerstein
Efpeglenatide and Clinical Outcomes with and without Concomitant Sodium-Glucose Co-Transporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. Circulation (2021)
Ki Young Huh, Jun Gi Hwang, Wonjung Shin, SeungJae Baek, JaeDuk Choi, Nora Lee, Young Min Cho, Howard Lee
A double-blind, placebo-controlled, single-ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HM15136, a novel long-acting glucagon analogue, in healthy subjects. Diabetes, obesity & metabolism (2021)